Mega Lifesciences Management
Management criteria checks 2/4
Mega Lifesciences' CEO is Vivek Dhawan, appointed in Jan 1988, has a tenure of 38.42 years. directly owns 6.66% of the company’s shares, worth THB2.03B. The average tenure of the management team and the board of directors is 28.4 years and 13.3 years respectively.
Key information
Vivek Dhawan
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 38.4yrs |
| CEO ownership | 6.7% |
| Management average tenure | 28.4yrs |
| Board average tenure | 13.3yrs |
Recent management updates
Recent updates
Narrative Update • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.Narrative Update • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Narrative Update • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Narrative Update • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).Narrative Update • Apr 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Narrative Update • Mar 23
MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
Narrative Update • Mar 09
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.Narrative Update • Feb 23
MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.Narrative Update • Feb 09
MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.Narrative Update • Jan 25
MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.Narrative Update • Jan 10
MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.Narrative Update • Dec 24
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.Narrative Update • Dec 09
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.Narrative Update • Nov 25
MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.New Narrative • Jun 01
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.CEO
Vivek Dhawan (65 yo)
38.4yrs
Tenure
Mr. Vivek Dhawan is CEO & Executive Director of Mega Lifesciences Public Company Limited from 2013 and serves as its Head of ESG & Chief Coach. He joined the Mega Lifesciences Public Company Limited in 198...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Head of ESG | 38.4yrs | no data | 6.66% THB 2.0b | |
| CFO, Head Coach & Executive Director | 28.4yrs | no data | 0.76% THB 233.4m | |
| Chief Risk & Compliance Officer | no data | no data | no data | |
| President of International & Head Coach | no data | no data | 1.5% THB 458.0m | |
| President of Myanmar & Head Coach | no data | no data | no data | |
| President of Mega We Care Thailand & Head Coach | no data | no data | 1.48% THB 450.9m | |
| Corporate Secretary | no data | no data | no data | |
| Deputy Chief Financial Officer | 6.4yrs | no data | 0.000010% THB 3.1k | |
| Regional Finance Head at Mega LifeSciences Pty. Ltd. | no data | no data | no data |
28.4yrs
Average Tenure
59.5yo
Average Age
Experienced Management: MEGA's management team is seasoned and experienced (28.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Head of ESG | 13.4yrs | no data | 6.66% THB 2.0b | |
| CFO, Head Coach & Executive Director | 28.4yrs | no data | 0.76% THB 233.4m | |
| Independent Chairman | 13.3yrs | ฿1.65m | no data | |
| Non-Executive Director | 13.3yrs | ฿694.58k | 49.81% THB 15.2b | |
| Non-Executive Director | 13.3yrs | ฿694.58k | no data | |
| Non-Executive Director | 13.3yrs | ฿694.58k | 0.32% THB 97.5m | |
| Chairman Emeritus | less than a year | ฿2.32m | no data | |
| Non-Executive Director | 13.3yrs | ฿694.58k | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.1yrs | ฿1.20m | no data | |
| Independent Vice Chairman | 3.2yrs | ฿1.20m | no data | |
| Independent Director | less than a year | no data | no data |
13.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: MEGA's board of directors are seasoned and experienced ( 13.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 11:58 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mega Lifesciences Public Company Limited is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |